Problems with API solid state are often overlooked in drug development. Selecting a sub-optimal version, lack of polymorph control, and poor design of the API step can halt a clinical program or delay commercialisation.
Having managed a broad portfolio of API projects with accountability for crystallisation and solid state from pre-phase 1 to manufacturing, if your drug has these sorts of problems, then feel free to contact me.